Condition: Colon Carcinoma · Colorectal Carcinoma · Rectal Carcinoma · Sponsor: Emory University
This phase II trial studies how well giving zanidatamab before surgery (neoadjuvant) works in treating patients with colon and rectal cancer that is human epidermal growth factor receptor 2 positive (HER2+ve) who are planned for curative intent treatment. Zanidatamab is a monoclonal antibody that may interfere with the ability of tumor cells to grow and spread. A monoclonal antibody is a type of protein that can bind to certain targets in the body, such as molecules that cause the body to make an immune response (antigens).
This description comes directly from the study's public registry record.
Olumide B. Gbolahan, MBBS, MSc · 404-778-1900 · ogbolah@emory.edu
Patrick Sullivan, MD, FACS · 404-778-2656 · patrick.s.sullivan@emory.edu
Always discuss trial participation with your own doctor first.
| Emory University Hospital Midtown | Atlanta, Georgia, United States | Recruiting |
| Emory University Hospital | Atlanta, Georgia, United States | Recruiting |
| Emory Saint Joseph's Hospital | Atlanta, Georgia, United States | Recruiting |
| Emory Decatur Hospital | Decatur, Georgia, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07405476